Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited Ordinary Shares
(NY:
TEVA
)
39.82
+0.41 (+1.04%)
Delayed Quote
Updated: 12:02 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
↗
August 28, 2025
Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs.
Via
Investor's Business Daily
This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More
↗
August 28, 2025
Via
Stocktwits
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
August 28, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
August 21, 2025
Via
Benzinga
Earnings Scheduled For July 30, 2025
↗
July 30, 2025
Via
Benzinga
How Do Investors Really Feel About Teva Pharmaceutical Indus?
↗
June 05, 2025
Via
Benzinga
Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters
↗
August 20, 2025
Duquesne's billionaire boss bid adieu to Wall Street's hottest artificial intelligence (AI) stock in favor of one of the cheapest pharmaceutical stocks on the planet.
Via
The Motley Fool
Topics
Artificial Intelligence
How Is The Market Feeling About Teva Pharmaceutical Indus?
↗
August 18, 2025
Via
Benzinga
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
August 06, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
↗
July 30, 2025
Teva raised 2025 guidance for Austedo, Ajovy, and Uzedy after Q2 earnings beat estimates, despite missing revenue expectations.
Via
Benzinga
Topics
Earnings
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
↗
July 30, 2025
Teva stock is trading below key levels.
Via
Investor's Business Daily
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
July 30, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
↗
July 29, 2025
Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition.
Via
Benzinga
A Glimpse of Teva Pharmaceutical Indus's Earnings Potential
↗
July 29, 2025
Via
Benzinga
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters
↗
July 18, 2025
Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years.
Via
The Motley Fool
Topics
Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
↗
July 15, 2025
Via
Benzinga
Looking Into Teva Pharmaceutical Indus's Recent Short Interest
↗
July 10, 2025
Via
Benzinga
Teva Releases Q2 2025 Aide Memoire
June 26, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
↗
June 26, 2025
Via
Benzinga
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
June 26, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
June 25, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
↗
June 25, 2025
Via
The Motley Fool
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
June 16, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
↗
June 16, 2025
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
From
FN Media Group LLC
Via
GlobeNewswire
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
↗
June 06, 2025
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
↗
June 04, 2025
Via
Benzinga
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
June 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
June 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
